Achilles Therapeutics Company

Personalised cancer treatments. Achilles Therapeutics is a biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.
Technology: AgeTech Companies
Industry: Healthcare
Headquarters: United Kingdom
Founded Date: 2016-05-01
Employees Number: 1-10
Funding Status: IPO
Investors Number: 11
Total Funding: £113.2M
Estimated Revenue: $10M to $50M
Last Funding Type: Series B

Visit Website
info@achillestx.com
https://twitter.com/achillestx
Register and Claim Ownership